Argentina
· Delayed Price · Currency is ARS Bioceres Crop Solutions Statistics
Total Valuation
BCBA:BIOX has a market cap or net worth of ARS 46.84 billion. The enterprise value is 411.78 billion.
| Market Cap | 46.84B |
| Enterprise Value | 411.78B |
Important Dates
The next estimated earnings date is Monday, May 11, 2026.
| Earnings Date | May 11, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +0.13% |
| Shares Change (QoQ) | -0.00% |
| Owned by Insiders (%) | 1.31% |
| Owned by Institutions (%) | 15.54% |
| Float | 42.87M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.12 |
| PB Ratio | 0.30 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 0.41 |
| P/OCF Ratio | 0.39 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 20.11, with an EV/FCF ratio of 3.57.
| EV / Earnings | -1.18 |
| EV / Sales | 1.05 |
| EV / EBITDA | 20.11 |
| EV / EBIT | n/a |
| EV / FCF | 3.57 |
Financial Position
The company has a current ratio of 0.90, with a Debt / Equity ratio of 2.25.
| Current Ratio | 0.90 |
| Quick Ratio | 0.56 |
| Debt / Equity | 2.25 |
| Debt / EBITDA | 15.92 |
| Debt / FCF | 3.01 |
| Interest Coverage | -0.09 |
Financial Efficiency
Return on equity (ROE) is -27.58% and return on invested capital (ROIC) is -0.59%.
| Return on Equity (ROE) | -27.58% |
| Return on Assets (ROA) | -0.23% |
| Return on Invested Capital (ROIC) | -0.59% |
| Return on Capital Employed (ROCE) | -1.09% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | 534.57M |
| Profits Per Employee | -462.98M |
| Employee Count | 751 |
| Asset Turnover | 0.40 |
| Inventory Turnover | 2.02 |
Taxes
In the past 12 months, BCBA:BIOX has paid 12.09 billion in taxes.
| Income Tax | 12.09B |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -84.33% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -84.33% |
| 50-Day Moving Average | 786.53 |
| 200-Day Moving Average | 2,413.75 |
| Relative Strength Index (RSI) | 47.69 |
| Average Volume (20 Days) | 275,236 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, BCBA:BIOX had revenue of ARS 401.46 billion and -347.69 billion in losses. Loss per share was -5,470.71.
| Revenue | 401.46B |
| Gross Profit | 150.46B |
| Operating Income | -3.68B |
| Pretax Income | -78.58B |
| Net Income | -347.69B |
| EBITDA | 15.19B |
| EBIT | -3.68B |
| Loss Per Share | -5,470.71 |
Balance Sheet
The company has 16.06 billion in cash and 347.55 billion in debt, giving a net cash position of -331.49 billion.
| Cash & Cash Equivalents | 16.06B |
| Total Debt | 347.55B |
| Net Cash | -331.49B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 154.74B |
| Book Value Per Share | 1,747.05 |
| Working Capital | -49.87B |
Cash Flow
In the last 12 months, operating cash flow was 118.83 billion and capital expenditures -3.44 billion, giving a free cash flow of 115.39 billion.
| Operating Cash Flow | 118.83B |
| Capital Expenditures | -3.44B |
| Depreciation & Amortization | 18.25B |
| Net Borrowing | -96.48B |
| Free Cash Flow | 115.39B |
| FCF Per Share | n/a |
Margins
Gross margin is 37.48%, with operating and profit margins of -0.92% and -86.61%.
| Gross Margin | 37.48% |
| Operating Margin | -0.92% |
| Pretax Margin | -19.57% |
| Profit Margin | -86.61% |
| EBITDA Margin | 3.78% |
| EBIT Margin | -0.92% |
| FCF Margin | 28.74% |
Dividends & Yields
BCBA:BIOX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.13% |
| Shareholder Yield | -0.13% |
| Earnings Yield | -742.27% |
| FCF Yield | 246.34% |
Stock Splits
The last stock split was on January 24, 2024. It was a forward split with a ratio of 2.
| Last Split Date | Jan 24, 2024 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |